Literature DB >> 16178770

Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF.

Danica K Hickey1, Shisan Bao, Luke T Ikeda, Alison J Carey, Kenneth W Beagley.   

Abstract

Transcutaneous immunization (TCI) involves the direct application of antigen plus adjuvant to skin, taking advantage of the large numbers of Langerhans cells and other resident skin dendritic cells, that process antigen then migrate to draining lymph nodes where immune responses are initiated. We have used this form of immunization to protect mice against genital tract and respiratory tract chlamydial infection. Protection was associated with local antibody responses in the vagina, uterus and lung as well as strong Th1 responses in the lymph nodes draining the reproductive tract and lungs respectively. In this study we show that topical application of GM-CSF to skin enhances the numbers and activation status of epidermal dendritic cells. Topical application of GM-CSF also increased the immune responses elicited by TCI. GM-CSF supplementation greatly increased cytokine (IFNgamma and IL-4) gene expression in lymph node and splenic cells compared to cells from animals immunized without GM-CSF. IgG responses in serum, uterine lavage and bronchoalveolar lavage and IgA responses in vaginal lavage were also increased by topical application of GM-CSF. The studies show that TCI induces protection against genital and respiratory tract chlamydial infections and that topical application of cytokines such as GM-CSF can enhance TCI-induced antibody and cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178770     DOI: 10.2174/1566524054863906

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  6 in total

Review 1.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

2.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

3.  Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.

Authors:  Saurabh Dixit; Shree R Singh; Abebayehu N Yilma; Ronald D Agee; Murtada Taha; Vida A Dennis
Journal:  Nanomedicine       Date:  2014-03-04       Impact factor: 5.307

4.  Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.

Authors:  Connor P O'Meara; Charles W Armitage; Marina C G Harvie; Peter Timms; Nils Y Lycke; Kenneth W Beagley
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

5.  CCL5 regulation of mucosal chlamydial immunity and infection.

Authors:  Senthilkumar K Sakthivel; Udai P Singh; Shailesh Singh; Dennis D Taub; Joseph U Igietseme; James W Lillard
Journal:  BMC Microbiol       Date:  2008-08-13       Impact factor: 3.605

Review 6.  Transcutaneous antigen delivery system.

Authors:  Mi-Young Lee; Meong-Cheol Shin; Victor C Yang
Journal:  BMB Rep       Date:  2013-01       Impact factor: 4.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.